Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A
1(100.0%)
1Total
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT06099912Recruiting

Individualized Dynamic Frailty-tailored Therapy (DynaFiT) in Elderly Patients With NDMM

Role: lead

NCT07045168Not Yet Recruiting

Risk-adapted Therapeutic Strategy in +1q NDMM

Role: lead

NCT06946407Not ApplicableRecruiting

Rituximab, Methotrexate, and Tepadina Induction Followed by Etoposide and Cytarabine Consolidation in Primary Central Nervous System Lymphoma

Role: lead

NCT06109233Recruiting

A Perspective Study of the MRD-tailored Therapy in Patients With Newly Diagnosed Multiple Myeloma With Persistent Minimal Residual Disease After Initial Treatment

Role: lead

NCT06252792Not Yet Recruiting

Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma

Role: lead

All 5 trials loaded